Delivery Order SPE2DB24D1021-SPE2DB25FFAJL
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,432.43 to AmerisourceBergen Drug Corp for Veozah 45 mg tablets (30-count packaging) on August 19, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its corporate office...
- The Defense Logistics Agency awarded a $2,768.73 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Veozah 45 mg tablets (30-count) on September 5, 2025, with an ultimate completion date of September 8, 2025. The contract is non-set-aside and competitively awarded, with performance to be completed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,541.30 to AmerisourceBergen Drug Corp for the supply of Veozah 45 mg tablets (30-unit package) on July 14, 2025, with an ultimate completion date of July 15, 2025. This competitive award utilized firm fixed pricing with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $3,715.38 to AmerisourceBergen Drug Corp for Veozah 45 mg tablets (30-count) on September 8, 2025, with completion targeted for September 9, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Veozah 45 mg tablets (30-count units) at a ceiling value of $1,582.61. This competitive award, which carries no set-aside designation, represents a firm fixed price delivery order and is expected to be completed by September 11, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,976.56 to AmerisourceBergen Drug Corp for the supply of Veozah 45 mg tablets (30-count) on May 30, 2025, with an ultimate completion date of June 2, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's broader...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,414.80 to AmerisourceBergen Drug Corp for the supply of Veozah 45 mg tablets (30-count packages). This firm fixed-price, non-set-aside delivery order was awarded on August 27, 2025, with an ultimate completion date of August 28, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued under a larger indefinite delivery contract...
- The Defense Logistics Agency awarded a delivery order valued at $2,467.93 to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Veozah 45 mg tablets (30-count packages). This non-set-aside, competitively awarded contract employs firm fixed-price pricing and requires completion by June 18, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,266.24 to AmerisourceBergen Drug Corp for the supply of Veozah 45 mg tablets (30-count units) on September 11, 2025, with an ultimate completion date of September 12, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion vehicle running through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Veozah 45 mg tablets in quantities of 30 units. This competitive award, with a ceiling value of $6,521.93, represents a firm fixed-price delivery order with an ultimate completion date of September 4, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen Drug Corp maintains its corporate office. This delivery...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FFAJLDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $16,183.30 to AmerisourceBergen Drug Corp for the supply of Veozah 45 mg tablets (30-count units). The award was made on September 8, 2025, with an ultimate completion date of September 9, 2025, under firm fixed price terms with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Health Agency and related federal customers. The company's federal contract portfolio demonstrates extensive capability in supplying brand-name and generic medications across multiple therapeutic domains. This competitive award reflects AmerisourceBergen's established position as a primary pharmaceutical supplier to DLA, with the SPE2DX contract serving as the foundational vehicle enabling flexible fulfillment of federal medical supply requirements globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.2k | 9/8/25 |